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Korea’s National Healthcare Program, the National Health Insurance Service (NHIS), a government-affiliated agency under the 
Korean Ministry of Health and Welfare, covers the entire Korean population. The NHIS supervises all medical services in Korea 
and establishes a systematic National Health Information database (DB). A health information DB system including all of the 
claims, medications, death information, and health check-ups, both in the general population and in patients with various diseas-
es, is not common worldwide. On June 9, 2014, the NHIS signed a memorandum of understanding with the Korean Diabetes As-
sociation (KDA) to provide limited open access to its DB. By October 31, 2017, seven papers had been published through this 
collaborative research project. These studies were conducted to investigate the past and current status of type 2 diabetes mellitus 
and its complications and management in Korea. This review is a brief summary of the collaborative projects between the KDA 
and the NHIS over the last 3 years. According to the analysis, the national health check-up DB or claim DB were used, and the age 
category or study period were differentially applied.
Keywords: Antidiabetic medication; Cardiovascular diseases; Depression; Diabetes mellitus, type 2; Diabetic retinopathy; Na-
tional Health Insurance Service
Corresponding author: Kyung-Soo Ko  https://orcid.org/0000-0002-8838-9094 
Division of Endocrinology and Metabolism, Department of Internal Medicine, Inje 
University Sanggye Paik Hospital, Inje University College of Medicine, 1342 Dongil-ro, 
Nowon-gu, Seoul 01757, Korea 
E-mail: kskomd@paik.ac.kr
Received: Dec. 19, 2017; Accepted: Mar. 4, 2018
INTRODUCTION
According to the recently published report of the Korea Na-
tional Health and Nutritional Examination Survey 2011, which 
is a cross-sectional health surveillance program on a nation-
wide scale, 4 million Koreans aged 30 years or older have dia-
betes, and the prevalence of diabetes was 12.4% [1,2]. In 2016, 
diabetes was ranked as the sixth cause of death and the most 
common cause of renal replacement therapy in Korea [3,4]. 
According to the annual report on Health Insurance Statistics 
by the Korean National Health Insurance Service (NHIS) and 
the Korean Health Insurance Review & Assessment (KHIRA) 
Service, diabetes ranked third in medical expenses as a single 
disease in Korea in 2015 [1]. 
The systematic care for chronic illnesses with large socioeco-
nomic and health burdens such as type 2 diabetes mellitus 
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(T2DM) is a very important health issue. For the establishment 
of management policies and improvement in the quality of 
care of this chronic metabolic disease, an accurate analysis of 
the current nationwide database (DB) on health information 
would be an initial step. The Korean NHIS program covers the 
computerized DB containing all of the claim data, including 
patient demographics, drug prescriptions, diagnostic codes for 
the disease coding system, the International Classification of 
Diseases (ICD), insurers’ payment coverage, patients’ deduc-
tion, and claimed treatment details [5,6]. The NHIS DB repre-
sents the entire Korean population; therefore, it can be used in 
a population-based nationwide study for T2DM in Korea. 
SOURCE OF DATABASE AND DEFINITION 
OF T2DM 
Among the total datasets of the NHIS DB, we used qualifica-
tions, claims, the health check-up DB, and death information. 
The claim DB consists of four categories, including general in-
formation on specifications, consultation statements, diagnosis 
statements classified by the International Classification of Dis-
eases 10th revision (ICD-10), and detailed information about 
prescriptions [5-7]. To extract the health information of the 
general population, we used the DB from the general health 
check-up. Due to the inevitable limitations of the claim DB, 
T2DM and related diseases were defined operationally (Table 
1). To validate the information accuracy, an expert committee 
from the Korean Diabetes Association (KDA) reviewed the DB 
regularly during this analysis. The committee decided the suit-
ability of the dataset and reviewed the results of the analysis.
Among all of the beneficiaries of the NHIS, retrospective 
data for adult patients with T2DM aged 30 years or older were 
extracted from January 2002 through December 2013. Patients 
were classified as having T2DM when they had at least one 
service claim with a diagnosis of T2DM based on ICD-10 
codes E11, E12, E13, or E14, as either the principal diagnosis 
or the first to fourth additional diagnosis, and were prescribed 
at least one antidiabetic drug anytime in a given year to ex-
clude prediabetes or non-diabetic subjects [7]. Type 1 diabetes 
mellitus, gestational diabetes, and subjects with missing data 
Table 1. The operational definitions of type 2 diabetes mellitus and its related comorbidities
Operational definition of diagnosis
Type 2 diabetes mellitus from claim DB ICD-10 code of type 2 diabetes mellitus (E11-E14) as principal diagnosis or up to a fourth 
additional diagnosis+prescribed at least one antidiabetic drug in a given year
Type 2 diabetes mellitus from health check-up DB FBG ≥126 mg/dL (undiagnosed diabetes) or ICD-10 code of type 2 diabetes mellitus 
with a claim for antidiabetic medication 
Hypertension from claim DB ≥1 Claim/year for antihypertensive medication under ICD-10 code of I10-I13, I15 
Dyslipidemia from claim DB ≥1 Claim/year for antidyslipidemic agents under ICD-10 code of E78 
Antidiabetic medications Sulfonylurea, metformin, DPP-4 inhibitor, alpha-glucosidase inhibitor, meglitinide, thia-
zolidinedione, insulins
Diabetic retinopathy 
Panretinal/endolaser photocoagulation
Pars plana vitrectomy
Visual impairment 
H36.0 
H36.0+S5160a/H36.0+S5161a
H36.0+S5121a
Registered in the National Handicapped Registry 
Ischemic heart disease I20-25
Acute myocardial infarction I21-23
Ischemic stroke I63, I64, I693, I694, G45
Hemorrhagic stroke I60-62, I690-692
Percutaneous coronary intervention (PCI)a M6551-2, M6561-4, M6571-2
Coronary artery bypass graft (CABG)a O1641-2, O6147, OA641-2, OA647
Depression F32-F34
DB, database; ICD-10, International Classification of Disease 10th revision; FBG, fasting blood glucose; DPP-4, dipeptidyl peptidase-4.
aProcedure codes. 
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were excluded. All of the ambulatory visits and any reason for 
hospitalizations with ICD-10 codes of T2DM were included. 
Using the national health examination DB, subjects with fast-
ing blood glucose levels ≥126 mg/dL without a claim for anti-
diabetic medication under the ICD-10 code (undiagnosed dia-
betes) were also considered as having diabetes. This study was 
approved by the Institutional Review Board of the Korean Na-
tional Institute for Bioethics Policy (P01-201504-21-005). In-
formed consent was exempted by the board. 
From this analytical process, the prevalence of T2DM based 
on the claim DB, trends in diabetic complications and the pre-
scription patterns of antidiabetic drugs, and depression in Ko-
rean adult patients with T2DM are summarized in this report. 
PREVALENCE AND INCIDENCE OF T2DM 
We defined T2DM by the NHIS claim DB only if the subjects 
had visited a healthcare institution and had antidiabetic medi-
cations or by the health check-up DB if they showed high fast-
ing glucose levels (≥126 mg/dL) without a claim for antidia-
betic medication under the ICD-10 code of T2DM (Table 1). 
Based on this claim DB, the prevalence of T2DM increased 
0.2% to 0.5% annually, from 5.6% (1,655,495 patients) in 2006 
to 8.0% (2,720,777 patients) in 2013 [8]. The incidence of 
T2DM was 0.81% in 2013 and increased with age [8]. The inci-
dence of T2DM was 1.4 times higher in men than in women 
(Table 2). The prevalence of impaired fasting glucose (glucose 
levels of 100 to 125 mg/dL without antidiabetic medications or 
an ICD-10 code of T2DM in the health check-up DB) in-
creased from 21.5% in 2006 to 25.0% in 2013 (Table 2). 
In addition, hypertension (62.5% vs. 16.9%) and dyslipid-
emia (45.9% vs. 9.7%) were more prevalent in patients with 
T2DM than in non-diabetic adults, respectively. In contrast, 
the control rate of hypertension from the health check-up DB 
was significantly lower in patients with T2DM compared to 
non-diabetic subjects (75.8% vs. 87.1%, P<0.001) [8]. 
CHANGES IN PRESCRIPTION PATTERNS OF 
ANTIDIABETIC MEDICATIONS 
We analyzed the trends in the prescription patterns of antidia-
betic agents in T2DM, such as sulfonylurea (SU), metformin, 
α-glucosidase inhibitor, meglitinide, dipeptidyl peptidase-4 
(DPP-4) inhibitor, thiazolidinedione, and insulin. Sodium-
glucose co-transporter-2 inhibitor, which was introduced in 
2015, and glucagon-like peptide-1 receptor agonist, which had 
Table 2. Prevalence and incidence of type 2 diabetes mellitus from 2006 to 2013 
2006 2007 2008 2009 2010 2011 2012 2013
Claim DB
   Total population 29,340,486 29,964,692 30,784,595 31,446,745 32,113,334 32,755,158 33,397,816 33,897,232
   Prevalence rate, % 5.6 6.1 6.4 6.8 7.1 7.5 7.8 8.0
      Sex 
         Men 6.0 6.5 6.9 7.4 7.7 8.2 8.5 8.8
         Women 5.3 5.7 6.0 6.3 6.6 6.9 7.1 7.3
   Incidence rate, % 0.95 0.93 0.90 0.91 0.88 0.90 0.83 0.81
      Sex 
         Men 1.07 1.04 1.03 1.02 0.99 1.03 0.97 0.94
         Women 0.84 0.83 0.79 0.80 0.76 0.78 0.71 0.68
Health check-up DB
   Total population 7,229,856 6,642,441 8,284,141 9,186,594 10,225,856 10,456,856 11,015,182 10,610,669
   Prevalence rate, % 8.4 9.0 8.9 9.9 9.9 10.3 10.5 10.9
      Sex 
         Men 9.2 9.6 9.9 11.0 11.2 11.5 11.9 12.2
         Women 7.3 8.1 7.5 8.5 8.4 8.7 8.8 9.3
   IFG, % 21.5 23.0 22.6 24.2 23.8 23.7 24.0 25.0
DB, database; IFG, impaired fasting glucose.
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limited insurance coverage, were not included in the analysis. 
Among 870,000 patients with T2DM who were treated with 
antidiabetic agents, SU was the most commonly used (87.2%), 
and metformin held the next rank (52.9%) in 2002 [7]. During 
the past decade, the use of metformin increased steadily to 
80.4% of total antidiabetic drug prescriptions and was the most 
frequently prescribed antidiabetic agent in Korea in 2013. The 
Clinical Practice Guidelines of the KDA recommend that ac-
tive lifestyle modification and the appropriate use of antidia-
betic agents are needed following the initial diagnosis of 
T2DM. Metformin is the preferred initial oral antidiabetic 
agent [9,10]. Therefore, the proportion of metformin use is ex-
pected to be maintained constant at the current level. 
Since the introduction of DPP-4 inhibitors in Korea at the 
end of 2008, its use has increased dramatically, comprising 
one-third of the Korean market share (38.4%) in 2013. The 
prescription of insulin increased to 19.1% of all patients with 
T2DM in 2008 and then was maintained as a constant over 
time (Table 3) [7]. 
Among antidiabetic prescriptions, the proportion of mono-
therapy declined from 58.4% in 2002 to 39.5% in 2013 [7]. In 
contrast, dual and triple combination therapy steadily in-
creased from 35.0% and 6.6% in 2002 to 44.9% and 15.5% in 
2013, respectively (P for trend <0.0001) [7]. In 2002, SU with 
metformin was the most frequently used dual therapy combi-
nation (68.7%). However, in 2013, SU with metformin (41.7%) 
and metformin with DPP-4 inhibitors (32.5%) dual combina-
tion therapies were the most frequently prescribed. According 
to the increased number of patients with T2DM, total antidia-
betic pharmacy expenditures dramatically increased from 83 
billion won in 2002 to 582 billion won in 2013 [7]. In addition, 
the mean payment per patient per year for antidiabetic medi-
cation was about 90,000 won in 2002 and 180,000 won in 2013. 
DIABETIC RETINOPATHY IN T2DM 
Diabetic retinopathy (DR), which is one of the chronic diabe-
tes-related vascular complications, is a troublesome complica-
tion and significantly increases medical costs [11,12]. In Korea, 
there was a steady increase in the prevalence of DR, from 
14.3% in 2006 (n=237,267) to 15.9% (n=431,964) in 2013 [13]. 
The prevalence of DR was higher in female patients than in 
males. The proportion of patients who underwent an annual 
fundus examination improved from 24.3% in 2006 to 30.0% in 
2013. In other words, more than two-thirds of patients with 
T2DM did not have their fundus checked in a year. However, 
the proportion of patients with T2DM who received laser 
treatments or underwent vitrectomy constantly decreased over 
the last decade. In 2006, among the patients with DR, 2.4% un-
derwent vitrectomy and 11.4% received laser treatments, com-
pared to 1.7% and 6.9%, respectively, in 2013 (P<0.0001) [13]. 
Accordingly, the percentage of patients with visual impairment 
who had a best-corrected visual acuity of <0.1 among DR pa-
tients decreased from 2.0% (4,820/237,267) in 2006 to 0.8% 
(3,572/431,964) in 2013 (Fig. 1) [13].
CARDIOVASCULAR COMPLICATIONS IN 
T2DM 
A long-standing hyperglycemia, insulin resistance, hyperten-
sion, and dyslipidemia cause various metabolic and molecular 
changes within the myocardium and coronary vessels [14]. 
These factors play pivotal roles in the development of cardiac 
dysfunction, diabetic cardiomyopathy, or cardiovascular (CV) 
Table 3. The use of antidiabetic medications (%) among people with diagnosed type 2 diabetes mellitus
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Insulin 8.6 9.5 11.5 14.8 17.3 18.7 19.1 18.6 17.8 17.6 17.3 16.4
SU 87.2 86.2 85.5 84.3 82.9 81.5 80.0 76.7 70.7 66.2 62.1 58.5
Metformin 52.9 56.6 59.0 59.7 60.9 62.9 64.9 68.9 72.3 76.9 79.1 80.4
Glinide 1.0 2.9 3.5 4.1 5.0 6.1 6.3 5.4 4.8 3.6 2.6 2.0
TZD 7.3 9.4 10.5 11.0 11.5 10.7 11.4 13.0 11.2 8.2 6.6 6.5
DPP-4i - - - - - - 0.3 8.4 13.9 19.0 28.7 38.4
α-GI 24.3 24.4 23.0 22.0 23.9 24.4 24.6 22.8 21.4 18.5 13.4 9.4
Total 181.3 189.0 193.0 196.0 201.5 204.4 206.6 213.7 212.0 210.1 209.8 211.7
SU, sulfonylurea; TZD, thiazolidinedione; DPP-4i, dipeptidyl peptidase-4 inhibitor; α-GI, α-glucosidase inhibitor. 
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disease, although multiple complex mechanisms and contrib-
ute to its pathogenesis [14,15].
Using the claim DB, six diabetes-related CV complications, 
including ischemic heart disease, acute myocardial infarction 
(AMI), ischemic stroke, hemorrhagic stroke, percutaneous 
coronary intervention, and coronary artery bypass graft, were 
investigated (Table 1). In the population with T2DM over 30 
years and older, the age and gender standardized rates of the 
above six CV outcomes decreased in Korea during the study 
period. Among them, hospitalization from AMI (–37.3%) and 
ischemic stroke (–37.0%) dramatically decreased between 
2006 and 2013 in T2DM [16]. In the general population with-
out T2DM, hospitalization from hemorrhagic stroke (–29.5%) 
and ischemic stroke (–28.9%) represented the largest drops. 
Moreover, the relative decrease in all six CV complications was 
profound in adults with T2DM compared to those in the gen-
eral population [16]. But subjects with T2DM continued to 
show a two- to six-fold higher risk of hospitalization due to 
major CV complications (Fig. 2) and CV interventions (Fig. 3) 
Fig. 1. Trends in diabetic retinopathy in patients with type 2 
diabetes mellitus in Korea, 2006 to 2013. 
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than people without T2DM. We suggest this reduced rate of 
CV outcomes in patients with T2DM seems to be related to the 
recent trend of improved control rates of hypertension, dyslip-
idemia, smoking cessation, and glycemic control in T2DM in 
Korea [17].
DEPRESSION IN T2DM 
Previously, the prevalence of depression in patients with 
T2DM in Korea has been reported as high as 22.6% to 28.8% 
[18,19]. In the analysis using the NHIS DB, depression in 
T2DM was defined as both T2DM and depression (ICD-10 
code of F320-349) with at least one prescription for antidepres-
sants (Table 1) [20].
According to the analysis of the NHIS DB from 2003 to 
2013, the annual prevalence rates of depression consistently 
increased both in T2DM and the general population without 
T2DM (Fig. 4) [20]. During the study period, the prevalence 
rate of depression in T2DM was about two-fold higher com-
pared to the general population (9.6% vs. 4.6% in 2013). In ad-
dition, T2DM patients with depression demonstrated a signifi-
cantly higher mortality risk than those without depression, es-
pecially in males and younger age groups [20]. The 10-year 
mortality rate in T2DM with depression was 1.4-fold higher 
compared to T2DM without depression, particularly for those 
in their 30s and 40s [20].
LIMITATIONS OF THIS ANALYSIS
There are some limitations in this analysis [5-7]. First, because 
health insurance coverage is confined to the allowable range of 
the recommendations for antidiabetic drug combinations 
made by the KHIRA Service in Korea, prescriptions not cov-
ered by health insurance were missed in this analysis. In addi-
tion, the NHIS DB does not contain uninsured prescriptions 
or over-the-counter drugs. Second, medical aid (MA) benefi-
ciary information has been incorporated into a single NHIS 
DB only since 2006; therefore, the NHIS DB included only in-
formation on NHIS beneficiaries, not MA beneficiaries, from 
2002 to 2005. Third, due to the characteristics of the claim DB, 
discrepancies between the actual diagnosis and claim data 
might be possible. Our reported number may not be the actual 
number of diabetic patients because not every patient who had 
T2DM visited a clinic or used antidiabetic medication, and not 
all patients with prescriptions visited the pharmacy and ob-
tained the medication. Fourth, this analysis relied only on 
claims data; we therefore could not obtain clinical information 
on glucose or glycosylated hemoglobin levels, diabetic dura-
tion, or reasons for nonadherence.
Fig. 4. Annual prevalence rates of depression in patients with 
type 2 diabetes mellitus (T2DM) and the general population 
without T2DM in Korea, 2003 to 2013.
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CLINICAL IMPLICATIONS AND FUTURE 
DIRECTIONS 
Despite steady improvements in screening, early detection of 
diabetes, and diabetes care in Korea, the absolute number of 
patients with T2DM remains high. A large and relevant eco-
nomic burden remains. Considering the importance of T2DM 
as a national health issue, the accurate estimation of the use of 
antidiabetic medications and understanding of diabetes-relat-
ed complications would be valuable information for the estab-
lishment of health policies and the setting of intervention tar-
get priorities. Healthcare professionals, academic expert 
groups such as the KDA, and government agencies should 
work together to find solutions for the health promotion to 
Korean patients with T2DM. From this respect, collaborative 
research by the NHIS and the KDA would be a good first step.
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